LianBio (LIAN): Price and Financial Metrics

LianBio (LIAN): $0.32

0.03 (-8.28%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add LIAN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#140 of 362

in industry

LIAN Price/Volume Stats

Current price $0.32 52-week high $4.99
Prev. close $0.35 52-week low $0.27
Day low $0.28 Volume 2,485,000
Day high $0.35 Avg. volume 1,037,083
50-day MA $4.30 Dividend yield N/A
200-day MA $3.08 Market Cap 34.47M

LIAN Stock Price Chart Interactive Chart >


LianBio (LIAN) Company Bio


Lianbio operates in the healthcare industry focusing on pharmaceutical business. The company is based in Camana Bay, Cayman Islands.


LIAN Latest News Stream


Event/Time News Detail
Loading, please wait...

LIAN Latest Social Stream


Loading social stream, please wait...

View Full LIAN Social Stream

Latest LIAN News From Around the Web

Below are the latest news stories about LIANBIO that investors may wish to consider to help them evaluate LIAN as an investment opportunity.

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

SHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radio

Yahoo | December 26, 2023

LianBio Announces Departure of Chief Financial Officer

SHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023. In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interi

Yahoo | December 20, 2023

LianBio Announces Departure of Chief Executive Officer

SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities. In connection with his departure, the LianBio Board of Directors has appointed Adam Stone, Chief Investment Officer of Perceptive Advisors and member of the LianBio

Yahoo | December 19, 2023

LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

SHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive

Yahoo | December 6, 2023

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

SHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio. Accordin

Yahoo | December 1, 2023

Read More 'LIAN' Stories Here

LIAN Price Returns

1-mo -93.36%
3-mo -92.84%
6-mo -78.52%
1-year -81.71%
3-year N/A
5-year N/A
YTD -92.84%
2023 172.56%
2022 -73.38%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!